Idiopathic intracranial hypertension (IIH) or benign intracranial hypertension is a neurological syndrome characterized by elevated intracranial pressure. This uncommon disorder occurs primarily in obese women aged 10 to 50 years, sometimes in association with endocrine and metabolic dysfunction, with systemic diseases or when treated with multiple medications.
BACKGROUND:
Idiopathic intracranial hypertension (IIH) or benign intracranial hypertension is a neurological syndrome characterized by elevated intracranial pressure. Though its origin seems to be dependent on multiple factors, most cases remain idiopathic (1, 3, 5, 7, 10, 15, 17) . This uncommon disorder occurs primarily in obese women aged 10 to 50 years, sometimes in association with endocrine and metabolic dysfunction, with systemic diseases or when treated with multiple medications (2, 7, 8, 14) . The association between some exogenous substances, such as drugs, and the development of IIH is well documented. Tetracycline antibiotics (tetracycline, monocycline, doxycycline), vitamin A and other retinoids, as well as corticosteroid withdrawal, are considered to be the most frequent causes (6, 9) . For others however a causal relationship is uncertain: amiodarone, growth hormone, levodopa, cyclosporine, oral contraceptives, oxytocin, indomethacin, lithium carbonate (7, 14, 16, 17) . Only few cases have been described about the influence of these drugs on the development of IIH, and on the other hand, follow-up after their withdrawal is not always long enough. Moreover, drug withdrawal is not reported to be curative only in all patients. It is therefore very important and useful to examine closely and describe such cases.
The clinical features of IIH are generally those of increased intracranial pressure: frontal headaches, nausea or vomiting, photophobia, transient visual obscurations, and occasionally progressive visual loss or diplopia (1, 3, 15, 17) .
We describe a case of IIH in a 43-year-old woman with schizophrenia treated with risperidone, demonstrating a typical clinical picture of benign intracranial hypertension. In our report, special attention is paid to etiology.
CASE REPORT:
We demonstrate a case of 43-year old female with schizophrenia diagnosed 10 years ago, and treated with risperidone for 5 years (4 mg daily). One month after initiation of treatment with risperidone the patient noted weight gain of 6 kg, and for the 5 years of treatment she put on 35 kg in total, despite her efforts to keep a strict diet (BMI> 35). Another 3 years later she began to complain of menstrual irregularities and headache. Elevated prolactine level and impaired glucose tolerability were found. The patient has complained of visual obscurations, nausea with vomiting for the last 2-3 months. Neuro-ophthalmologic evaluation showed normal visual acuity of 20/20 (1.0). Ophthalmoscopy revealed bilateral asymmetric papilledema (OD>OS) (Fig.1) . Ocular motility, cover test and pupil reaction were normal. Threshold visual field testing shower enlarged blind spots.
Magnetic resonance imaging was normal. Intracranial pressure was elevated (34 cm H2O); cerebrospinal fluid was normal. IIH was diagnosed. Risperidone was discontinued and replaced with Seroquel 200 mg daily. Treatment with furosemide (Lasix -2x40 mg) and mannitol 10% (3x150 ml i.v.) was initiated. The patient was placed on a strict diet again. Papilledema resolved completely over the next 2 months.
The patient was followed-up for four years after risperidone withdrawal. Schizophrenia has been treated successfully with Seroquel 150 mg daily. Weight loss of 28 kg was noted for four years. There were no relapses of headache, nausea, visual obscuration, menstrual irregularities and hyperprolactinaemia. Ophthalmologic examination revealed no papilledema (Fig.2) .
DISCUSSION:
IIH is a rare disorder, associated with several conditions and risk factors: obesity, weight gain, use of tetracycline antibiotics, vitamin A and other retinoids (3, 5, 7, 8, 15, 17) . Numerous drugs, including psychotherapeutics, have been associated with IIH, but a causal relationship is only supported by single cases. In some instances visual and neurological disorders in IIH can continue or a relapse may appear despite medication withdrawal. In a small number of patients IIH was associated with lithium use, and in some cases, re-challenge resulted in reappearance of IIH (11,13).
In our case, a woman with schizophrenia treated for 5 years with risperidone, developed IIH with a typical clinical picture. Soon after initiation of treatment, weight gain was observed, followed by hormonal problems: menstrual irregularities and hyperprolactinaemia. Risperidone can cause sustained hyperprolactinaemia. Weight gain is a well-known adverse effect of risperidone, and at the same time it is associated with greater risk of IIH (4, 12) . It could be discussed that in the described case IIH was mainly associated with weight gain, secondary to prolonged use of risperidone, and not with risperidone itself. After Risperidone withdrawal, the four-year follow-up period showed significant weight reduction, normal hormonal state, and no relapses of IIH.
CONCLUSION:
The association based upon reports of single cases are insufficient to support a causal relationship between risperidone and IIH. More descriptions of similar cases, as well as longer follow-up are needed. However, prolonged use of antipsychotics, such as risperidone, should require proper surveillance for possible development of IIH and routine ophthalmologic examinations should be performed. 
